<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Radiol Short Rep</journal-id><journal-id journal-id-type="iso-abbrev">Acta Radiol Short Rep</journal-id><journal-id journal-id-type="publisher-id">ARR</journal-id><journal-id journal-id-type="hwp">sparr</journal-id><journal-title-group><journal-title>Acta Radiologica Short Reports</journal-title></journal-title-group><issn pub-type="epub">2047-9816</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25298866</article-id><article-id pub-id-type="pmc">4184378</article-id><article-id pub-id-type="doi">10.1177/2047981614531573</article-id><article-id pub-id-type="publisher-id">10.1177_2047981614531573</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A longitudinal VBM study monitoring treatment with erythropoietin in patients with Friedreich ataxia</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Santner</surname><given-names>Wolfram</given-names></name><xref ref-type="aff" rid="aff1-2047981614531573">1</xref></contrib><contrib contrib-type="author"><name><surname>Schocke</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff2-2047981614531573">2</xref></contrib><contrib contrib-type="author"><name><surname>Boesch</surname><given-names>Sylvia</given-names></name><xref ref-type="aff" rid="aff3-2047981614531573">3</xref></contrib><contrib contrib-type="author"><name><surname>Nachbauer</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="aff3-2047981614531573">3</xref></contrib><contrib contrib-type="author"><name><surname>Egger</surname><given-names>Karl</given-names></name><xref ref-type="aff" rid="aff4-2047981614531573">4</xref></contrib></contrib-group><aff id="aff1-2047981614531573"><label>1</label>Department of Radiology, Kantonsspital Baden, Switzerland</aff><aff id="aff2-2047981614531573"><label>2</label>Department of Radiology, Innsbruck Medical University, Austria</aff><aff id="aff3-2047981614531573"><label>3</label>Department of Neurology, Innsbruck Medical University, Austria</aff><aff id="aff4-2047981614531573"><label>4</label>Department of Neuroradiology, University Medical Center Freiburg, Germany</aff><author-notes><corresp id="corresp1-2047981614531573">Wolfram Santner, Department of Radiology, Kantonsspital Baden, Im Ergel 1, 5404 Baden, Switzerland. Email: <email>wolfram.santner@ksb.ch</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>5</month><year>2014</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2014</year></pub-date><volume>3</volume><issue>4</issue><elocation-id>2047981614531573</elocation-id><history><date date-type="received"><day>23</day><month>2</month><year>2014</year></date><date date-type="accepted"><day>24</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; The Foundation Acta Radiologica 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement><copyright-year>2014</copyright-year><copyright-holder content-type="society">The Foundation Acta Radiologica</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/3.0/">http://www.creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(<ext-link ext-link-type="uri" xlink:href="http://www.uk.sagepub.com/aboutus/openaccess.htm">http://www.uk.sagepub.com/aboutus/openaccess.htm</ext-link>).</license-p></license></permissions><abstract><sec><title>Background</title><p>Recombinant human erythropoietin (rhuEPO) has received considerable attention because of its neuroprotective properties. It has recently been reported that rhuEPO increases frataxin levels in combination with clinical improvement in rhuEPO treated patients with Friedreich ataxia (FRDA).</p></sec><sec><title>Purpose</title><p>To determine possible therapy dependent intracranial volume changes after treatment with rhuEPO using voxel-based morphometry (VBM).</p></sec><sec><title>Material and Methods</title><p>Nine FRDA patients were scanned on the same 1.5-Tesla MRI scanner before and after treatment with rhuEPO. FRDA patients received 5000&#x02009;IU rhuEPO thrice weekly subcutaneously for a time period of 8 weeks followed by 2000&#x02009;IU thrice weekly over 6 months. To test for re-test reliability a control group of 12 healthy volunteers were scanned twice on the same scanner without rhuEPO treatment. Neurological state was defined by the Friedreich Ataxia Rating Scale (FARS) and the Scale for the Assessment and Rating of Ataxia (SARA). Statistical parametric mapping software was used for image processing and statistical analysis.</p></sec><sec><title>Results</title><p>When comparing follow-up scans after rhuEPO treatment with baseline scans (<italic>P</italic> &#x0003c;0.001 uncorrected) an increase of gray matter volume was observed bilaterally in the Pulvinar and the posterior parietal cortex. Moreover, clinical improvement detected using specific Ataxia scores correlated with VBM results in the pulvinar.</p></sec><sec><title>Conclusion</title><p>Given the limitation of a small sample size, our study confirms previous findings that MRI may serve as reliable biomarker in neurodegenerative diseases as well as in monitoring of microstructural changes representing disease progression and/or therapy effects.</p></sec></abstract><kwd-group><kwd>CNS</kwd><kwd>thalamus</kwd><kwd>parietal cortex</kwd><kwd>Friedreich ataxia</kwd><kwd>voxel-based morphometry</kwd><kwd>erythropoietin</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>edited-state</meta-name><meta-value>corrected-proof</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-2047981614531573"><title>Introduction</title><p>Friedreich ataxia (FRDA) is the most common inherited ataxia and in most cases due to a gene repeat expansion which provides instructions for producing an enzyme called &#x0201c;glucosidase alpha acid&#x0201d; (GAA) on chromosome 9q13 coding for a mitochondrial protein named Frataxin (<xref rid="bibr1-2047981614531573" ref-type="bibr">1</xref>).</p><p>Neuropathological studies have shown that FRDA is characterized by neuronal loss and white matter (WM) tract degeneration in the spinal cord, brainstem and cerebellum (<xref rid="bibr2-2047981614531573" ref-type="bibr">2</xref>). A magnetic resonance imaging (MRI) study using voxel-based morphometry (VBM) in FRDA patients revealed symmetrical volume loss in dorsal medulla and cerebellum as compared to controls. Both atrophy of the cerebellum and medulla correlated with clinical severity and disease duration (<xref rid="bibr3-2047981614531573" ref-type="bibr">3</xref>).</p><p>Recombinant human erythropoietin (rhuEPO) has received considerable attention because of its neuroprotective and cardioprotective properties (<xref rid="bibr4-2047981614531573" ref-type="bibr">4</xref><xref rid="bibr5-2047981614531573" ref-type="bibr"/><xref rid="bibr6-2047981614531573" ref-type="bibr"/><xref rid="bibr7-2047981614531573" ref-type="bibr"/>&#x02013;<xref rid="bibr8-2047981614531573" ref-type="bibr">8</xref>). An <italic>in&#x000a0;vitro</italic> study found that rhuEPO increases frataxin levels in isolated lymphocytes from FRDA patients. Subsequently, we were able to show significant increase in frataxin-levels in FRDA patients treated with rhuEPO in a two months &#x0201c;proof-of-concept&#x0201d; study and clinical improvement in a 6-month follow-up study (<xref rid="bibr9-2047981614531573" ref-type="bibr">9</xref><xref rid="bibr10-2047981614531573" ref-type="bibr"/>&#x02013;<xref rid="bibr11-2047981614531573" ref-type="bibr">11</xref>). Furthermore a recent diffusion tensor imaging (DTI) study (<xref rid="bibr12-2047981614531573" ref-type="bibr">12</xref>) revealed rather unspecific increase in fractional anisotropy (FA) in the cerebral hemispheres bilateraly in FRDA patients after rhuEPO treatment.</p><p>VBM is designed to detect significant regional MRI signal differences <italic>in&#x000a0;vivo</italic> by applying voxel-wise statistics in the context of Gaussian random fields (<xref rid="bibr13-2047981614531573" ref-type="bibr">13</xref><xref rid="bibr14-2047981614531573" ref-type="bibr"/>&#x02013;<xref rid="bibr15-2047981614531573" ref-type="bibr">15</xref>). The aim of this study was to detect therapy dependent intracranial volume changes using VBM in FRDA patients after treatment with rhuEPO.</p></sec><sec sec-type="materials|methods" id="sec2-2047981614531573"><title>Material and Methods</title><sec id="sec3-2047981614531573" sec-type="subjects"><title>Subjects</title><p>Nine adult FRDA patients (6 men, 3 women, mean age at onset, 21.5 years; mean duration of disease, 14.5 years; GAA repeat length range between 240 and 1000) (<xref ref-type="table" rid="table1-2047981614531573">Table 1</xref>) and a control group of 12 healthy volunteers (6 men, 6 women; mean age at examination, 25.4 years) were examined twice on the same MR scanner within this VBM study. Neurological state defined by the Friedreich Ataxia Rating Scale (FARS) in FRDA patients was 59.83 points (range, 36&#x02013;86 points) (<xref rid="bibr16-2047981614531573" ref-type="bibr">16</xref>). The Scale for the Assessment and Rating of Ataxia (SARA) revealed mean 20 points (range, 13&#x02013;27 points) (<xref rid="bibr17-2047981614531573" ref-type="bibr">17</xref>).
<table-wrap id="table1-2047981614531573" position="float"><label>Table 1.</label><caption><p>Demographic and clinical parameters of study participants.</p></caption><table frame="hsides" rules="groups"><thead align="left" valign="top"><tr><th rowspan="1" colspan="1">Age* (years)/Sex</th><th rowspan="1" colspan="1">GAA repeats</th><th rowspan="1" colspan="1">DD</th><th rowspan="1" colspan="1">SARA</th><th rowspan="1" colspan="1">FARS</th></tr></thead><tbody align="left" valign="top"><tr><td rowspan="1" colspan="1">26/M</td><td rowspan="1" colspan="1">650</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">56</td></tr><tr><td rowspan="1" colspan="1">26/M</td><td rowspan="1" colspan="1">1000</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">26.5</td><td rowspan="1" colspan="1">86</td></tr><tr><td rowspan="1" colspan="1">46/M</td><td rowspan="1" colspan="1">800</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">23.5</td><td rowspan="1" colspan="1">68</td></tr><tr><td rowspan="1" colspan="1">51/F</td><td rowspan="1" colspan="1">190</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">20.5</td><td rowspan="1" colspan="1">44.5</td></tr><tr><td rowspan="1" colspan="1">29/F</td><td rowspan="1" colspan="1">320</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">52</td></tr><tr><td rowspan="1" colspan="1">32/M</td><td rowspan="1" colspan="1">370</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">14.5</td><td rowspan="1" colspan="1">36</td></tr><tr><td rowspan="1" colspan="1">29/F</td><td rowspan="1" colspan="1">1000</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">25.5</td><td rowspan="1" colspan="1">83</td></tr><tr><td rowspan="1" colspan="1">18/M</td><td rowspan="1" colspan="1">500</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">49</td></tr><tr><td rowspan="1" colspan="1">41/M</td><td rowspan="1" colspan="1">420</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">64</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1-2047981614531573"><p>Patient ID in accordance with prior publication on this sample (<xref rid="bibr11-2047981614531573" ref-type="bibr">11</xref>).</p></fn><fn id="table-fn2-2047981614531573"><p>*Age at study entry.</p></fn><fn id="table-fn3-2047981614531573"><p>DD, disease duration (years); FARS, Friedreich Ataxia Rating Scale; GAA, number of trinucleotide repeats on the shorter allele; SARA, Scale for the Assessment and Rating of Ataxia.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec4-2047981614531573"><title>Study design</title><p>In an open-label, phase II, proof-of-concept study FRDA patients received 5000&#x02009;IU rhuEPO thrice weekly subcutaneously for a time period of 8 weeks followed by 2000&#x02009;IU rhuEPO thrice weekly over 6 months (<xref rid="bibr9-2047981614531573" ref-type="bibr">9</xref>). The healthy control group received no rhuEPO.</p></sec><sec id="sec5-2047981614531573"><title>MR assessment</title><p>MR assessment was performed according a predefined protocol before and after treatment with rhuEPO. Additional exclusion criteria for MR assessment were metal in the body that precludes MRI and agoraphobia. The MR assessment of the healthy control group was performed in an interval of 2 months (baseline scan, follow-up scan 2 months later). All MRI scans were proofed by an experienced radiologist (MS) to avoid structural abnormalities or artifacts.</p></sec><sec id="sec6-2047981614531573"><title>Data acquisition</title><p>All participants were scanned on the same 1.5 Tesla MRI scanner (Magnetom Avanto, Siemens, Erlangen, Germany) using a T1-weighted 3D sequence with a repetition time (TR) of 9.7&#x02009;ms, an echo time (TE) of 4&#x02009;ms, a matrix size of 256&#x02009;&#x000d7;&#x02009;256, and a field of view of 230&#x02009;mm. The resulting sagittal slices had a thickness of 1.5&#x02009;mm and an in-plane resolution of 0.98&#x02009;&#x000d7;&#x02009;0.98&#x02009;mm.</p></sec><sec id="sec7-2047981614531573"><title>Voxel based morphometry (VBM)</title><p>Statistical parametric mapping software (SPM2; The Wellcome Department of Cognitive Neurology, London, UK) was used for image processing and statistical analysis. We applied the optimized VBM protocol to the image data as reported by Good et&#x000a0;al. (<xref rid="bibr15-2047981614531573" ref-type="bibr">15</xref>). This protocol includes a study specific template, extraction of miss-segmented areas and the modulation of the data with the Jacobian determinants.</p><p>The creation of the study group-specific template was performed to minimize the scanner specific bias by averaging all images from the study specific subject group, after being normalized using linear 12-parameter affine-only transformation. Custom tissue probability maps were obtained by segmenting the individual normalized images into gray matter (GM), white matter (WM), and cerebrospinal fluid (CSF), averaging and smoothing with an isotropic Gaussian kernel of 8&#x02009;mm full-width at half maximum (FWHM).</p><p>The optimized VBM protocol includes two segmentation steps. First segmentation was performed in native space and non-brain tissue was removed automatically by modulation with an individually derived brain-tissue mask. Second segmentation was performed after applying the normalization parameters to the original whole brain images (as described below) including once again removing of non-brain tissue followed by re-slicing onto a voxel size of 1&#x02009;&#x000d7;&#x02009;1&#x02009;&#x000d7;&#x02009;1&#x02009;mm.</p><p>The spatial normalization parameters were estimated by matching the native spaced individual GM image with the study-specific GM template using combined 12 parameter linear and non-linear (7&#x02009;&#x000d7;&#x02009;9&#x02009;&#x000d7;&#x02009;7 basic functions) transformation. The parameters resulting from this spatial normalization step were then reapplied to the original structural images.</p><p>Multiplying voxel values of the segmented images with the Jacobian determinants was implemented to convert the GM segments into measures of absolute gray matter volume (GMV), as opposed to relative GMV, following spatial normalization.</p><p>Finally, all modulated images were smoothed with a 10&#x02009;mm FWHM Gaussian kernel to reduce confounding by individual variation in gyral anatomy. This also has the effect of rendering the data more normally distributed (by the central limit theorem) (<xref rid="bibr13-2047981614531573" ref-type="bibr">13</xref>,<xref rid="bibr14-2047981614531573" ref-type="bibr">14</xref>).</p><p>Smoothed and segmented gray matter partitions have been subjected for statistical analysis choosing the factorial design &#x0201c;paired t-test&#x0201d;.</p><p>The statistical parametric maps were thresholded at <italic>P</italic> uncorrected &#x0003c;0.001 with an extent threshold of 20 contiguous voxels. Finally, smoothed GM segments were entered into a voxel-based multiple regression analysis to investigate linear correlations between GM volume and primary clinical outcome measures (FARS and SARA) (<xref rid="bibr10-2047981614531573" ref-type="bibr">10</xref>).</p></sec></sec><sec sec-type="results" id="sec8-2047981614531573"><title>Results</title><p>When comparing the follow-up scans after treatment with recombinant human erythropoietin (rhuEPO) with the baseline scans an increase of GMV (<xref ref-type="table" rid="table2-2047981614531573">Table 2</xref>) was observed bilaterally in the posterior part of the thalamus (pulvinar) (<xref ref-type="fig" rid="fig1-2047981614531573">Fig. 1</xref>) and in the posterior parietal lobe (Brodmann area 7) (<xref ref-type="fig" rid="fig2-2047981614531573">Fig. 2</xref>) (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 uncorrected).
<fig id="fig1-2047981614531573" position="float"><label>Fig. 1.</label><caption><p>Areas of subcortical GMV increase when baseline MR scans of patients with Friedreich ataxia are compared to the follow-up scans after treatment with recombinant human erythropoietin (rHuEPO). Results are superimposed on the slices of a T1-weighted mean-picture (a) axial, (b) coronal, and on the slices of a modulated mean picture (c) sagital, (d) coronal, (e) axial of all study participants. The color bars give the corresponding Z-scores. Threshold was set at T&#x02009;=&#x02009;3.4 (corresponding to a <italic>P</italic> value of &#x0003c;0.001 uncorrected).</p></caption><graphic xlink:href="10.1177_2047981614531573-fig1"/></fig>
<fig id="fig2-2047981614531573" position="float"><label>Fig. 2.</label><caption><p>Results in SPM render-style show areas of cortical GMV increase when baseline MR scans of patients with Friedreich ataxia are compared to the follow-up scans after treatment with recombinant human erythropoietin (rHuEPO). Threshold was set at T&#x02009;=&#x02009;3.4 (corresponding to a <italic>P</italic> value of &#x0003c;0.001 uncorrected).</p></caption><graphic xlink:href="10.1177_2047981614531573-fig2"/></fig>
<table-wrap id="table2-2047981614531573" position="float"><label>Table 2.</label><caption><p>Relative increase of gray matter volume in patients with Friedreich ataxia after treatment with recombinant human erythropoietin (rHuEPO) relative to baseline examination before treatment (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 uncorrected).</p></caption><table frame="hsides" rules="groups"><thead align="left" valign="top"><tr><th rowspan="3" colspan="1">Region</th><th rowspan="3" colspan="1"/><th rowspan="3" colspan="1">BA</th><th colspan="4" rowspan="1">Significant differences in gray matter<hr/></th></tr><tr><th colspan="3" rowspan="1">MNI coordinates*<hr/></th><th rowspan="1" colspan="1">Peak gray matter change<hr/></th></tr><tr><th rowspan="1" colspan="1">x</th><th rowspan="1" colspan="1">y</th><th rowspan="1" colspan="1">z</th><th rowspan="1" colspan="1">Z-score</th></tr></thead><tbody align="left" valign="top"><tr><td rowspan="3" colspan="1">Parietal lobe</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Right</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">&#x02013;69</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">3.50</td></tr><tr><td rowspan="1" colspan="1">Left</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">&#x02013;9</td><td rowspan="1" colspan="1">&#x02013;76</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">4.16</td></tr><tr><td rowspan="3" colspan="1">Thalamus/ Pulvinar</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Right</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">&#x02013;28</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">3.41</td></tr><tr><td rowspan="1" colspan="1">Left</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02013;16</td><td rowspan="1" colspan="1">&#x02013;31</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">3.61</td></tr></tbody></table><table-wrap-foot><fn id="table-fn4-2047981614531573"><p>*Coordinates are given in MNI space (Montreal Neurological Institute).</p></fn></table-wrap-foot></table-wrap></p><p>There were no regions showing significant decrease in GMV, and there was no significant group difference in white matter volume (WMV).</p><p>Correlation analysis (Spearman rank correlation analysis performed with SPSS, Version 15; SPSS Inc., Chicago, IL, USA) for FRDA patients revealed an association between age at onset of disease and GAA repeat length (R&#x02009;=&#x02009;&#x02212;0.927, <italic>P</italic>&#x02009;=&#x02009;0.003). Voxel-based multiple regression analysis showed that there were significant correlations between GMV in rather unspecific cortical and subcortical structures and individual clinical ataxia scores such as SARA and FARS. Additionally, scores in SARA and FARS showed a significant negative correlation (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 uncorrected) with increased GMV in the pulvinar and posterior parietal cortex bilaterally. The healthy control group showed no significant change of GMV (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 uncorrected).</p></sec><sec sec-type="discussion" id="sec9-2047981614531573"><title>Discussion</title><p>In the last years, the non-erythroid, especially neuroprotective functions of EPO have been increasingly recognized. These functions probably base on suppression of apoptosis and promotion of neurogenesis, as suggested by several experimental animal studies (<xref rid="bibr18-2047981614531573" ref-type="bibr">18</xref><xref rid="bibr19-2047981614531573" ref-type="bibr"/><xref rid="bibr20-2047981614531573" ref-type="bibr"/><xref rid="bibr21-2047981614531573" ref-type="bibr"/><xref rid="bibr22-2047981614531573" ref-type="bibr"/><xref rid="bibr23-2047981614531573" ref-type="bibr"/><xref rid="bibr24-2047981614531573" ref-type="bibr"/><xref rid="bibr25-2047981614531573" ref-type="bibr"/>&#x02013;<xref rid="bibr26-2047981614531573" ref-type="bibr">26</xref>).</p><p>In the present study, we report on a volume increase in the dorsal thalamus (Pulvinar) measured with the help of VBM in a patient collective with FRDA, receiving EPO over a period of several months. As our initial VBM analysis had shown no changes in primary disease-specific areas (e.g. cerebellum), we also looked for supratentorial changes, in accordance with previously published DTI results (<xref rid="bibr12-2047981614531573" ref-type="bibr">12</xref>) within the same study collective. This pulvinar volume increase correlated with an improvement in ataxia rating scales. Additional significant volume increase was found in the posterior parietal cortex, where higher association areas are in permanent interaction with the pulvinar. Parietal association areas play a major role in linking incoming sensory information with the primary motor area. This is of major interest, as FRDA is an autosomal-recessive neurodegenerative disorder mainly affecting sensory neurons in the dorsal root ganglia as well as the spinocerebellar tract, pyramidal tract and the dorsal columns (<xref rid="bibr27-2047981614531573" ref-type="bibr">27</xref>).</p><p>Underlying mechanisms of dynamic structural alterations detected by VBM are not entirely clear. Macroscopic alterations may be based on changes at the level of synaptic bulk, or they might include increased cell genesis of glial and/or neuronal cells. EPO has been shown to enhance the levels of BDNF (brain derived neurotropic factor) (<xref rid="bibr28-2047981614531573" ref-type="bibr">28</xref>) which results in an improvement of the mTOR (mammalian target of rapamycin) pathway, representing an integral cell growth regulator (<xref rid="bibr29-2047981614531573" ref-type="bibr">29</xref>), which might result in changes of cellular volume.</p><p>Another study administering large systemic doses of rhEPO in mice revealed transient enhancement of hippocampal neurogenesis (<xref rid="bibr30-2047981614531573" ref-type="bibr">30</xref>).</p><p>PET studies investigating glucose metabolism in FRDA patients have shown that glucose metabolism is initially increased in several brain regions like brain stem, cerebellum, and thalamus and declines with disease severity (<xref rid="bibr31-2047981614531573" ref-type="bibr">31</xref>). Alternatively, altered regional volume as measured in our VBM study might therefore be related to an improvement of energy supply in the dorsal thalamus.</p><p>Since our healthy control group showed no significant changes over time, it can be assumed that VBM with longer intra-individual scan intervals is a stable method. This finding is in accordance with a recent study showing that regional GMV was relatively stable within the same scanner, but can significantly change when comparing images acquired on different scanners (<xref rid="bibr32-2047981614531573" ref-type="bibr">32</xref>).</p><p>Given the limitation of small sample size in this pilot study further confirmation of our findings are of major interest. Future interventional animal studies combining structural and functional MRI with histological verification are needed to enlighten the impact of MRI in monitoring of microstructural changes representing disease progression and/or therapy effects.</p><p>In conclusion, our study confirms previous findings that MRI may serve as reliable biomarker in neurodegenerative diseases as well as in monitoring of microstructural changes representing disease progression and/or therapy effects.</p></sec></body><back><ref-list><title>References</title><ref id="bibr1-2047981614531573"><label>1</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Klockgether</surname><given-names>T</given-names></name></person-group>
<source>Handbook of ataxia disorders</source>, <publisher-loc>New York</publisher-loc>: <publisher-name>Marcel Dekker</publisher-name>, <year>2000</year></mixed-citation></ref><ref id="bibr2-2047981614531573"><label>2</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>J</given-names></name><name><surname>Lennox</surname><given-names>G</given-names></name><name><surname>Leigh</surname><given-names>PN</given-names></name></person-group>
<source>Disorders of movement and system degeneration. Greenfield's Neuropathology</source>, <edition>6th edn</edition>
<publisher-loc>New York</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>, <year>1997</year></mixed-citation></ref><ref id="bibr3-2047981614531573"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Della Nave</surname><given-names>R</given-names></name><name><surname>Ginestroni</surname><given-names>A</given-names></name><name><surname>Giannelli</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Brain structural damage in Friedreich's ataxia</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2008</year>; <volume>79</volume>: <fpage>82</fpage>&#x02013;<lpage>85</lpage><pub-id pub-id-type="pmid">17634216</pub-id></mixed-citation></ref><ref id="bibr4-2047981614531573"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogoyevitch</surname><given-names>MA</given-names></name></person-group>
<article-title>An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection</article-title>. <source>Cardiovasc Res</source>
<year>2004</year>; <volume>63</volume>: <fpage>208</fpage>&#x02013;<lpage>216</lpage><pub-id pub-id-type="pmid">15249178</pub-id></mixed-citation></ref><ref id="bibr5-2047981614531573"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juul</surname><given-names>S</given-names></name></person-group>
<article-title>Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage</article-title>. <source>Acta Paediatr Suppl</source>
<year>2002</year>; <volume>91</volume>: <fpage>36</fpage>&#x02013;<lpage>42</lpage><pub-id pub-id-type="pmid">12477263</pub-id></mixed-citation></ref><ref id="bibr6-2047981614531573"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Maeda</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>RR</given-names></name><name><surname>Elkabes</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Beneficial effect of erythropoietin on experimental allergic encephalomyelitis</article-title>. <source>Ann Neurol</source>
<year>2004</year>; <volume>56</volume>: <fpage>767</fpage>&#x02013;<lpage>777</lpage><pub-id pub-id-type="pmid">15562412</pub-id></mixed-citation></ref><ref id="bibr7-2047981614531573"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siren</surname><given-names>AL</given-names></name><name><surname>Ehrenreich</surname><given-names>H</given-names></name></person-group>
<article-title>Erythropoietin&#x02013;a novel concept for neuroprotection</article-title>. <source>Eur Arch Psychiatry Clin Neurosci</source>
<year>2001</year>; <volume>251</volume>: <fpage>179</fpage>&#x02013;<lpage>184</lpage><pub-id pub-id-type="pmid">11697582</pub-id></mixed-citation></ref><ref id="bibr8-2047981614531573"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>KJ</given-names></name><name><surname>Bleyer</surname><given-names>AJ</given-names></name><name><surname>Little</surname><given-names>WC</given-names></name><etal/></person-group>
<article-title>The cardiovascular effects of erythropoietin</article-title>. <source>Cardiovasc Res</source>
<year>2003</year>; <volume>59</volume>: <fpage>538</fpage>&#x02013;<lpage>548</lpage><pub-id pub-id-type="pmid">14499855</pub-id></mixed-citation></ref><ref id="bibr9-2047981614531573"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boesch</surname><given-names>S</given-names></name><name><surname>Sturm</surname><given-names>B</given-names></name><name><surname>Hering</surname><given-names>S</given-names></name><name><surname>Goldenberg</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin</article-title>. <source>Ann Neurol</source>
<year>2007</year>; <volume>62</volume>: <fpage>521</fpage>&#x02013;<lpage>524</lpage><pub-id pub-id-type="pmid">17702040</pub-id></mixed-citation></ref><ref id="bibr10-2047981614531573"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boesch</surname><given-names>S</given-names></name><name><surname>Sturm</surname><given-names>B</given-names></name><name><surname>Hering</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: a clinical pilot trial</article-title>. <source>Mov Disord</source>
<year>2008</year>; <volume>23</volume>: <fpage>1940</fpage>&#x02013;<lpage>1944</lpage><pub-id pub-id-type="pmid">18759345</pub-id></mixed-citation></ref><ref id="bibr11-2047981614531573"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sturm</surname><given-names>B</given-names></name><name><surname>Stupphann</surname><given-names>D</given-names></name><name><surname>Kaun</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Recombinant human erythropoietin: effects on frataxin expression in&#x000a0;vitro</article-title>. <source>Eur J Clin Invest</source>
<year>2005</year>; <volume>35</volume>: <fpage>711</fpage>&#x02013;<lpage>717</lpage><pub-id pub-id-type="pmid">16269021</pub-id></mixed-citation></ref><ref id="bibr12-2047981614531573"><label>12</label><mixed-citation publication-type="other"><comment>Egger K, Clemm von Hohenberg C, Schocke MF, et&#x000a0;al. White Matter Changes in Patients with Friedreich Ataxia after Treatment with Erythropoietin. J Neuroimaging Epub ahead of print 9 September 2013. doi: 10.1111/jon.12050</comment></mixed-citation></ref><ref id="bibr13-2047981614531573"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashburner</surname><given-names>J</given-names></name><name><surname>Andersson</surname><given-names>JL</given-names></name><name><surname>Friston</surname><given-names>KJ</given-names></name></person-group>
<article-title>Image registration using a symmetric prior&#x02013;in three dimensions</article-title>. <source>Hum Brain Mapp</source>
<year>2000</year>; <volume>9</volume>: <fpage>212</fpage>&#x02013;<lpage>225</lpage><pub-id pub-id-type="pmid">10770230</pub-id></mixed-citation></ref><ref id="bibr14-2047981614531573"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashburner</surname><given-names>J</given-names></name><name><surname>Friston</surname><given-names>KJ</given-names></name></person-group>
<article-title>Voxel-based morphometry&#x02013;the methods</article-title>. <source>Neuroimage</source>
<year>2000</year>; <volume>11</volume>: <fpage>805</fpage>&#x02013;<lpage>821</lpage><pub-id pub-id-type="pmid">10860804</pub-id></mixed-citation></ref><ref id="bibr15-2047981614531573"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Good</surname><given-names>CD</given-names></name><name><surname>Johnsrude</surname><given-names>IS</given-names></name><name><surname>Ashburner</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>A voxel-based morphometric study of ageing in 465 normal adult human brains</article-title>. <source>Neuroimage</source>
<year>2001</year>; <volume>14</volume>: <fpage>21</fpage>&#x02013;<lpage>36</lpage><pub-id pub-id-type="pmid">11525331</pub-id></mixed-citation></ref><ref id="bibr16-2047981614531573"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz-Hubsch</surname><given-names>T</given-names></name><name><surname>du Montcel</surname><given-names>ST</given-names></name><name><surname>Baliko</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Scale for the assessment and rating of ataxia: development of a new clinical scale</article-title>. <source>Neurology</source>
<year>2006</year>; <volume>66</volume>: <fpage>1717</fpage>&#x02013;<lpage>1720</lpage><pub-id pub-id-type="pmid">16769946</pub-id></mixed-citation></ref><ref id="bibr17-2047981614531573"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramony</surname><given-names>SH</given-names></name></person-group>
<article-title>SARA&#x02013;a new clinical scale for the assessment and rating of ataxia</article-title>. <source>Nat Clin Pract Neurol</source>
<year>2007</year>; <volume>3</volume>: <fpage>136</fpage>&#x02013;<lpage>137</lpage><pub-id pub-id-type="pmid">17290240</pub-id></mixed-citation></ref><ref id="bibr18-2047981614531573"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>XB</given-names></name><name><surname>Wang</surname><given-names>JA</given-names></name><name><surname>Yu</surname><given-names>SP</given-names></name><etal/></person-group>
<article-title>Therapeutic strategy of erythropoietin in neurological disorders</article-title>. <source>CNS Neurol Disord Drug Targets</source>
<year>2008</year>; <volume>7</volume>: <fpage>227</fpage>&#x02013;<lpage>234</lpage><pub-id pub-id-type="pmid">18673207</pub-id></mixed-citation></ref><ref id="bibr19-2047981614531573"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grasso</surname><given-names>G</given-names></name><name><surname>Sfacteria</surname><given-names>A</given-names></name><name><surname>Meli</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>The role of erythropoietin in neuroprotection: therapeutic perspectives</article-title>. <source>Drug News Perspect</source>
<year>2007</year>; <volume>20</volume>: <fpage>315</fpage>&#x02013;<lpage>320</lpage><pub-id pub-id-type="pmid">17878959</pub-id></mixed-citation></ref><ref id="bibr20-2047981614531573"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwai</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>G</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats</article-title>. <source>Stroke</source>
<year>2007</year>; <volume>38</volume>: <fpage>2795</fpage>&#x02013;<lpage>2803</lpage><pub-id pub-id-type="pmid">17702962</pub-id></mixed-citation></ref><ref id="bibr21-2047981614531573"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>XF</given-names></name><name><surname>Fawcett</surname><given-names>JR</given-names></name><name><surname>Thorne</surname><given-names>RG</given-names></name><etal/></person-group>
<article-title>Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion</article-title>. <source>Neurosci Lett</source>
<year>2001</year>; <volume>308</volume>: <fpage>91</fpage>&#x02013;<lpage>94</lpage><pub-id pub-id-type="pmid">11457567</pub-id></mixed-citation></ref><ref id="bibr22-2047981614531573"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Qu</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice</article-title>. <source>J Neurosurg</source>
<year>2008</year>; <volume>109</volume>: <fpage>510</fpage>&#x02013;<lpage>521</lpage><pub-id pub-id-type="pmid">18759585</pub-id></mixed-citation></ref><ref id="bibr23-2047981614531573"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>YP</given-names></name><name><surname>Xu</surname><given-names>QQ</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group>
<article-title>Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia</article-title>. <source>Neurosci Lett</source>
<year>2005</year>; <volume>387</volume>: <fpage>5</fpage>&#x02013;<lpage>10</lpage><pub-id pub-id-type="pmid">16054296</pub-id></mixed-citation></ref><ref id="bibr24-2047981614531573"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siren</surname><given-names>AL</given-names></name><name><surname>Radyushkin</surname><given-names>K</given-names></name><name><surname>Boretius</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin</article-title>. <source>Brain</source>
<year>2006</year>; <volume>129</volume>: <fpage>480</fpage>&#x02013;<lpage>489</lpage><pub-id pub-id-type="pmid">16339796</pub-id></mixed-citation></ref><ref id="bibr25-2047981614531573"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sargin</surname><given-names>D</given-names></name><name><surname>Hassouna</surname><given-names>I</given-names></name><name><surname>Sperling</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Uncoupling of neurodegeneration and gliosis in a murine model of juvenile cortical lesion</article-title>. <source>Glia</source>
<year>2009</year>; <volume>57</volume>: <fpage>693</fpage>&#x02013;<lpage>702</lpage><pub-id pub-id-type="pmid">18985736</pub-id></mixed-citation></ref><ref id="bibr26-2047981614531573"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taoufik</surname><given-names>E</given-names></name><name><surname>Petit</surname><given-names>E</given-names></name><name><surname>Divoux</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>2008</year>; <volume>105</volume>: <fpage>6185</fpage>&#x02013;<lpage>6190</lpage><pub-id pub-id-type="pmid">18413601</pub-id></mixed-citation></ref><ref id="bibr27-2047981614531573"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fogel</surname><given-names>BL</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group>
<article-title>Clinical features and molecular genetics of autosomal recessive cerebellar ataxias</article-title>. <source>Lancet Neurol</source>
<year>2007</year>; <volume>6</volume>: <fpage>245</fpage>&#x02013;<lpage>257</lpage><pub-id pub-id-type="pmid">17303531</pub-id></mixed-citation></ref><ref id="bibr28-2047981614531573"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viviani</surname><given-names>B</given-names></name><name><surname>Bartesaghi</surname><given-names>S</given-names></name><name><surname>Corsini</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor</article-title>. <source>J Neurochem</source>
<year>2005</year>; <volume>93</volume>: <fpage>412</fpage>&#x02013;<lpage>421</lpage><pub-id pub-id-type="pmid">15816864</pub-id></mixed-citation></ref><ref id="bibr29-2047981614531573"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Inoki</surname><given-names>K</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group>
<article-title>mTOR pathway as a target in tissue hypertrophy</article-title>. <source>Annu Rev Pharmacol Toxicol</source>
<year>2007</year>; <volume>47</volume>: <fpage>443</fpage>&#x02013;<lpage>467</lpage><pub-id pub-id-type="pmid">16968213</pub-id></mixed-citation></ref><ref id="bibr30-2047981614531573"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ransome</surname><given-names>MI</given-names></name><name><surname>Turnley</surname><given-names>AM</given-names></name></person-group>
<article-title>Systemically delivered Erythropoietin transiently enhances adult hippocampal neurogenesis</article-title>. <source>J Neurochem</source>
<year>2007</year>; <volume>102</volume>: <fpage>1953</fpage>&#x02013;<lpage>1965</lpage><pub-id pub-id-type="pmid">17555554</pub-id></mixed-citation></ref><ref id="bibr31-2047981614531573"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilman</surname><given-names>S</given-names></name><name><surname>Junck</surname><given-names>L</given-names></name><name><surname>Markel</surname><given-names>DS</given-names></name><etal/></person-group>
<article-title>Cerebral glucose hypermetabolism in Friedreich's ataxia detected with positron emission tomography</article-title>. <source>Ann Neurol</source>
<year>1990</year>; <volume>28</volume>: <fpage>750</fpage>&#x02013;<lpage>757</lpage><pub-id pub-id-type="pmid">2285262</pub-id></mixed-citation></ref><ref id="bibr32-2047981614531573"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takao</surname><given-names>H</given-names></name><name><surname>Hayashi</surname><given-names>N</given-names></name><name><surname>Ohtomo</surname><given-names>K</given-names></name></person-group>
<article-title>Effects of the use of multiple scanners and of scanner upgrade in longitudinal voxel-based morphometry studies</article-title>. <source>J Magn Reson Imaging</source>
<year>2013</year>; <volume>38</volume>: <fpage>1283</fpage>&#x02013;<lpage>1291</lpage><pub-id pub-id-type="pmid">23371908</pub-id></mixed-citation></ref></ref-list></back></article>